Free Trial

Neoleukin Therapeutics (NLTX) Insider Trading & Ownership

Neoleukin Therapeutics logo
$15.33 -1.90 (-11.03%)
(As of 11/20/2024 ET)

Neoleukin Therapeutics (NASDAQ:NLTX) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
1.58%
Number Of
Insiders Buying
(Last 3 Years)
1
Amount Of
Insider Buying
(Last 3 Years)
$1.31 M
Number Of
Insiders Selling
(Last 3 Years)
2
Amount Of
Insider Selling
(Last 3 Years)
$11,770.80
Get NLTX Insider Trade Alerts

Want to know when executives and insiders are buying or selling Neoleukin Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

NLTX Insider Buying and Selling by Quarter

Neoleukin Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2023Bros. Advisors Lp BakerDirectorBuy8,347$13.80$115,188.60  
8/15/2023Bros. Advisors Lp BakerDirectorBuy94,440$12.60$1,189,944.00  
8/11/2023Sean Michael SmithCFOSell66$12.40$818.40  
4/3/2023Priti PatelInsiderSell188$13.80$2,594.40  
8/10/2022Sean Michael SmithInsiderSell82$19.80$1,623.60  
5/2/2022Priti PatelInsiderSell276$24.40$6,734.40  
(Data available from 1/1/2013 forward)

NLTX Insider Trading Activity - Frequently Asked Questions

The list of insiders at Neoleukin Therapeutics includes Bros. Advisors Lp Baker, Priti Patel, and Sean Michael Smith. Learn more on insiders at NLTX.

1.58% of Neoleukin Therapeutics stock is owned by insiders. Learn more on NLTX's insider holdings.

The following insider purchased NLTX shares in the last 24 months: Bros. Advisors Lp Baker ($1,305,132.60).

Insiders have purchased a total of 102,787 NLTX shares in the last 24 months for a total of $1,305,132.60 bought.

The following insiders have sold NLTX shares in the last 24 months: Priti Patel ($2,594.40), and Sean Michael Smith ($818.40).

Insiders have sold a total of 254 Neoleukin Therapeutics shares in the last 24 months for a total of $3,412.80 sold.

Neoleukin Therapeutics Key Executives

  • Ms. Donna M. Cochener-Metcalfe J.D. (Age 48)
    General Counsel, Interim CEO & Corporate Secretary
    Compensation: $403.75k
  • Dr. David Baker M.D.
    Ph.D., Co-Founder
  • Mr. Sean Michael Smith (Age 37)
    Interim Chief Financial Officer


This page (NASDAQ:NLTX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners